Drug Profile

Neuregulin 4 agonist - Eli Lilly and Company

Alternative Names: NRG4 agonist - Eli Lilly and Company

Latest Information Update: 29 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

29 May 2024 Neuregulin 4 agonist is still in phase I trial for Heart failure in USA (Eli Lilly and Company Pipeline, May 2024)
28 Sep 2023 No recent reports of development identified for phase-I development in Heart-failure in USA
11 Aug 2020 Phase-I clinical trials in Heart failure in USA (unspecified route), prior to August 2020 (Eli Lilly and Company pipeline, August 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com